In a breakthrough that could reshape modern drug development for the treatment of asthma and other conditions beyond pulmonary, researchers at Duke University School of Medicine in Durham, North Carolina, have uncovered a new way cells organize and control critical signals — by forming tiny, liquid-like droplets known as biomolecular condensates.
Their paper, “β-Arrestin Condensates Regulate G-Protein-Coupled Receptor Function,” published in Nature, focuses on proteins called β-arrestins. According to the study’s authors, these proteins have long been known to regulate G‑protein‑coupled receptors (GPCRs) — a massive class of receptors involved in nearly every aspect of human physiology, including asthma. Additionally, GPCRs are also among the most common targets for pharmaceuticals.
Until now, scientists understood that β-arrestins could bind to these receptors and orchestrate signaling. But exactly how they managed such a wide range of functions remained a mystery, researchers wrote. The results of their study demonstrate that β-arrestins don’t just float freely inside cells. They cluster together into droplet-like structures through a process called liquid–liquid phase separation.
“Our work shows that these receptors signal in a way we didn't fully appreciate before. That's important because it suggests new, potentially druggable ways to target GPCR signaling,” said senior author Sudarshan Rajagopal, MD, PhD, in a Duke news release. Dr. Rajagopal is an associate professor of medicine at the university.
Even under normal conditions, β-arrestins appear as small puncta — or dots — throughout cells, researchers explained. When GPCRs are activated, these clusters rapidly relocate to the cell membrane, where signaling begins.
Their discovery, they said, provides a compelling answer to a longstanding question: How do β-arrestins coordinate interactions with hundreds of different proteins? The study’s authors found that β-arrestins can:
- Concentrate signaling molecules in one location
- Control receptor internalization, the process by which receptors are pulled into the cell
- Fine-tune signaling pathways that govern cell growth, survival and response
According to researchers, their findings showed that disrupting these condensates with chemical treatments has major consequences that interfere with droplet formation. Specifically, authors observed:
- A sharp reduction in receptor internalization
- Altered cell signaling activity, particularly in pathways linked to ERK proteins
- Changes in how β-arrestins move and interact within the cell
In some cases, they said, receptor internalization was almost completely blocked, underscoring how essential these condensates are for normal cellular function.
Interestingly, not all receptors trigger the same type of β-arrestin clustering, they noted. Different GPCRs were shown to induce distinct patterns of β-arrestin organization, suggesting a highly precise and customizable signaling system. This means cells may tailor responses depending on the type of signal they receive — a level of specificity that could explain the complexity of GPCR-driven biology, the study determined.
Researchers said their findings carry significant implications for drug discovery to treat asthma and other conditions. Because GPCRs are targeted by a large percentage of medications, understanding how their signaling is regulated at a deeper level could open new therapeutic strategies.
Instead of simply activating or blocking receptors, researchers theorized that “context-dependent targeting of these condensates” might influence future drugs by:
- Modulating condensate formation
- Targeting specific signaling compartments
- Reducing side effects by fine-tuning cellular responses
